Related Experiment Video
Updated: May 11, 2026
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
Combined transfection of Bcl-2 siRNA and miR-15a oligonucleotides enhanced methotrexate-induced apoptosis in Raji
Li Ding1, Xiao-Mao Hu, Hong Wu
1Institute of Hematology, Jinan University, Guangzhou 510632, China.
Objective:
B-cell lymphoma 2 (Bcl-2) is an important member of the Bcl-2 family of proteins that regulate the induction of apoptosis. This study aims to investigate whether Bcl-2 small interfering RNA (siRNA) combined with miR-15a oligonucleotides (ODN) could enhance methotrexate (MTX)-induced apoptosis in Raji cells.
Methods:
Chemically synthesized miR-15a ODN and Bcl-2 siRNA were transfected in Raji cells by using a HiPerFect Transfection Reagent and then combined with MTX. Expression levels of Bcl-2 protein were detected by Western blot. Cell proliferation was determined by CCK8 assay. The rate of cell apoptosis was determined by Annexin V/PI double staining. The morphology of apoptotic cells was observed by Hoechst-33 258 staining.
Results:
After the cells were transfected with miR-15a ODN combined with Bcl-2 siRNA, Bcl-2 protein levels were evidently decreased. CCK8 assay showed that cell proliferation was significantly decreased and was significantly lower in miR-15a ODN combined with Bcl-2 siRNA plus MTX group than in miR-15a ODN with methotrexate group, Bcl-2 siRNA with MTX group, and single MTX group (P<0.05). Hoechst 33258 staining revealed numerous apoptotic cells. AnnexinV/PI double staining showed that the apoptotic rates were (13.13±1.60)%, (34.47±2.96)%, (32.87±3.48)%, and (45.47±2.16)% in MTX, Bcl-2 siRNA plus MTX, miR-15a ODN plus MTX, and miR-15a ODN combined with Bcl-2 siRNA plus MTX groups, respectively. Among these groups, the apoptotic rate of miR-15a ODN combined with Bcl-2 siRNA plus MTX group was the highest; this apoptotic rate was also significantly different from that of miR-15a ODN or Bcl-2 siRNA plus MTX (P<0.05).
Conclusions:
Bcl-2 siRNA combined with miR-15a ODN could enhance MTX-induced apoptosis in Raji cells. Bcl-2 siRNA and miR-15a combined with MTX may be a useful approach to improve the treatment effects on lymphoma.
Insights
Bcl-2 siRNA and miR-15a oligonucleotides enhance methotrexate-induced apoptosis in Raji cells. This combination therapy significantly boosts cell death rates, offering a promising strategy for lymphoma treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- Apoptosis Regulation
Background:
- B-cell lymphoma 2 (Bcl-2) is a key regulator of apoptosis.
- Dysregulation of Bcl-2 family proteins is implicated in various cancers, including lymphoma.
- Methotrexate (MTX) is a chemotherapeutic agent used in lymphoma treatment.
Purpose of the Study:
- To investigate the combined effect of Bcl-2 small interfering RNA (siRNA) and miR-15a oligonucleotides (ODN) on MTX-induced apoptosis in Raji cells.
- To determine if this combination enhances the efficacy of MTX in inducing cancer cell death.
Main Methods:
- Raji cells were transfected with chemically synthesized miR-15a ODN and Bcl-2 siRNA using HiPerFect Transfection Reagent.
- Cells were subsequently treated with MTX.
- Bcl-2 protein levels were assessed via Western blot.
- Cell proliferation was measured using CCK8 assay.
- Apoptosis rates were quantified by Annexin V/PI double staining and Hoechst 33258 staining.
Main Results:
- Co-transfection with miR-15a ODN and Bcl-2 siRNA significantly reduced Bcl-2 protein expression.
- The combination therapy (miR-15a ODN + Bcl-2 siRNA + MTX) resulted in the highest rate of apoptosis (45.47±2.16%).
- This combination significantly inhibited cell proliferation compared to MTX alone or in combination with either siRNA or ODN alone (P<0.05).
Conclusions:
- Bcl-2 siRNA combined with miR-15a ODN effectively enhances MTX-induced apoptosis in Raji cells.
- This combined approach demonstrates potential as an improved therapeutic strategy for lymphoma treatment.
- Targeting Bcl-2 and utilizing miR-15a alongside MTX may overcome resistance and improve treatment outcomes.
